AtlasXomics
PrivateLast Round
Grant
Apr 8, 2025
Total Funding Raised
$15.68M
Company Overview
AtlasXomics is a biotechnology company that develops a spatial epigenome technology platform designed to provide multi-omics tissue atlases for researchers and clinicians.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Biotech Equipment, Precision Medicine, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting, Hardware + Subscription, Usage-Based SaaS
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
AtlasXomics Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
AtlasXomics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Apr 8, 2025 | ||||
| Grant | Sep 19, 2023 | ||||
| Grant | Sep 16, 2022 | ||||
| Grant | May 1, 2022 | ||||
| Series A | Feb 8, 2022 | ||||
Seed | Mar 30, 2021 |
AtlasXomics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| National Cancer Institute | Grant |
| Connecticut Innovations | Seed, Series A |
| U.S. Department of Health and Human Services | Grant |
| NIH RADx | Grant |
| Elm Street Ventures | Seed |
| FORGE | Grant |
| Broadfield Capital | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 8, 2025
$70K grant received from FORGE.
AtlasXomics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about AtlasXomics's valuation, stock price, and market status.